SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
Authors
Keywords
-
Journal
ACS Chemical Biology
Volume 16, Issue 7, Pages 1223-1233
Publisher
American Chemical Society (ACS)
Online
2021-07-04
DOI
10.1021/acschembio.1c00272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
- (2021) Yin-Feng Kang et al. ACS Nano
- A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
- (2021) Tiong Kit Tan et al. Nature Communications
- Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
- (2021) Cyrielle Fougeroux et al. Nature Communications
- COVID-19 vaccines: rapid development, implications, challenges and future prospects
- (2021) Shivaji Kashte et al. Human Cell
- Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
- (2021) Kevin O. Saunders et al. NATURE
- Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
- (2021) Yury Valdes-Balbin et al. ACS Central Science
- Structure analysis of the receptor binding of 2019-nCoV
- (2020) Yun Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples
- (2020) Alessandro Manenti et al. JOURNAL OF MEDICAL VIROLOGY
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
- (2020) Jingyun Yang et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
- (2020) Chee Wah Tan et al. NATURE BIOTECHNOLOGY
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Structural basis of a shared antibody response to SARS-CoV-2
- (2020) Meng Yuan et al. SCIENCE
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
- (2020) Jinkai Zang et al. Cell Discovery
- Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
- (2020) Xiancai Ma et al. IMMUNITY
- The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world
- (2020) Kate Bingham LANCET
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
- (2020) Dani Cohen et al. LANCET INFECTIOUS DISEASES
- Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Neisseria meningitidis serogroup C
- (2019) Juned Dalal et al. VACCINE
- Targeting the hydrophilic regions of recombinant proteins by MS via in-solution buffer-free trypsin digestion
- (2019) Lázaro H Betancourt et al. EUROPEAN JOURNAL OF MASS SPECTROMETRY
- A Synthetic Carbohydrate Conjugate Vaccine Candidate against Shigellosis: Improved Bioconjugation and Impact of Alum on Immunogenicity
- (2016) Robert M. F. van der Put et al. BIOCONJUGATE CHEMISTRY
- Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: A randomized phase I clinical trial
- (2014) Carlos P. Dotres et al. VACCINE
- Protein carriers of conjugate vaccines: Characteristics, development and clinical trials
- (2013) Michael E Pichichero Human Vaccines & Immunotherapeutics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More